GlassScriptPhysician profile
Aliza Epstein
NPI 1205221652
$4,311.99
in general payments reported to CMS, 2019-2025
26 companies · $638 in 2025
The $638 reported for 2025 was more than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $75.45 · 2021: $476 · 2022: $865 · 2023: $798 · 2024: $514 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,950.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $786.71 | 2021-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $515.35 | 2022-2024 | Vyzulta |
| Tarsus Pharmaceuticals, INC. | $343.30 | 2025 | Xdemvy |
| Alcon Vision LLC | $323.59 | 2019-2025 | Clareon |
| Amgen INC. | $210.73 | 2024-2025 | Tepezza |
| Abbvie INC. | $208.25 | 2023-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $197.40 | 2020-2021 | |
| New World Medical,INC. | $175.74 | 2023 | |
| Novartis Pharmaceuticals Corporation | $159.83 | 2019 | |
| Glaukos Corporation | $153.15 | 2019 | |
| Genentech USA, INC. | $138.05 | 2021 | |
| Oyster Point Pharma, INC. | $133.64 | 2024 | Tyrvaya |
| Ocular Therapeutix, INC. | $124.44 | 2021 | |
| Mallinckrodt Enterprises LLC | $119.31 | 2019 | |
| Biotissue Holdings INC. | $118.51 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $117.87 | 2019 | |
| Shire North American Group INC | $114.85 | 2019 | |
| Optovue, INC. | $100.00 | 2019 | |
| Harrow Eye, LLC | $57.40 | 2025 | Iheezo |
| Allergan, INC. | $47.68 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $40.48 | 2025 | Purified Cortrophin Gel |
| Eyepoint US, INC. | $34.45 | 2021 | |
| Rxsight INC | $31.33 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Sun Pharmaceutical Industries INC. | $22.21 | 2023 | Cequa |
| Merz Pharmaceuticals, LLC | $21.63 | 2023 | Xeomin |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliza Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.